Corcept Therapeutics Incorporated
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CORT research report →
Companywww.corcept.com
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess.
- CEO
- Joseph K. Belanoff
- IPO
- 2004
- Employees
- 500
- HQ
- Menlo Park, CA, US
Price Chart
Valuation
- Market Cap
- $6.34B
- P/E
- 128.76
- P/S
- 8.24
- P/B
- 9.67
- EV/EBITDA
- -918.89
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.25%
- Op Margin
- -1.07%
- Net Margin
- 6.23%
- ROE
- 7.50%
- ROIC
- -1.23%
Growth & Income
- Revenue
- $761.41M · 12.79%
- Net Income
- $99.65M · -28.68%
- EPS
- $0.95 · -29.63%
- Op Income
- $44.80M
- FCF YoY
- -27.62%
Performance & Tape
- 52W High
- $91.00
- 52W Low
- $28.66
- 50D MA
- $43.77
- 200D MA
- $59.77
- Beta
- 0.35
- Avg Volume
- 1.52M
Get TickerSpark's AI analysis on CORT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | Robb Gary Charles | other | 5,300 |
| May 13, 26 | Robb Gary Charles | other | 1,000 |
| May 5, 26 | Guyer William | other | 20,000 |
| May 5, 26 | Guyer William | other | 20,000 |
| May 5, 26 | Guyer William | sell | 20,000 |
| May 1, 26 | BELANOFF JOSEPH K | sell | 40,000 |
| Apr 22, 26 | WILSON JAMES N | other | 2,000 |
| Apr 7, 26 | Guyer William | other | 20,000 |
| Apr 7, 26 | Guyer William | other | 20,000 |
| Apr 7, 26 | Guyer William | sell | 20,000 |
Our CORT Coverage
We haven't published any research on CORT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CORT Report →